Literature DB >> 34903371

Antibody responses of healthy adults to the p27 peptide of respiratory syncytial virus fusion protein.

Brittani N Blunck1, Letisha Aideyan1, Xunyan Ye1, Vasanthi Avadhanula1, Laura Ferlic-Stark1, Lynn Zechiedrich2, Brian E Gilbert1, Pedro A Piedra3.   

Abstract

The respiratory syncytial virus (RSV) fusion (F) protein undergoes two furin-cleavage events to become fusion competent, resulting in the release of a twenty-seven amino acid peptide (p27). Recent studies indicate that the p27 region of the F protein was an immunodominant antigen in young children. In this study, we evaluated the kinetics of the serum antibody response to the p27 peptide following natural RSV reinfection in adults. Nineteen healthy adults under sixty-five years of age were enrolled during the 2018-2019 RSV season in Houston, TX. Blood was collected at three study visits and RSV infection status was defined by changes in neutralizing antibody resulting in three groups: uninfected (n = 12), acutely infected (n = 4), and recently infected (n = 3). Serum IgG and IgA antibodies against RSV/A and RSV/B p27 peptides were measured by enzyme-linked immunosorbent assays, and serum p27-like antibodies were detected by a p27 competitive antibody assay. Anti-p27 antibodies were detected in all subjects at each study visit. The measured IgG and IgA anti-p27 antibody levels followed the same pattern as other RSV site-specific and neutralizing antibody responses described for this cohort previously: the uninfected group had stable responses for the duration of the study period, the acutely infected group had a significant increase following RSV infection, and the recently infected group had a decrease in anti-p27 antibody during the study period. These results indicate that antibodies to the p27 region of the F protein are generated following natural RSV reinfection and suggest that some of the F protein is potentially in a partially cleaved state on the surface of virions, expanding on the previous assumption that all of p27 is post-translationally released and not present on mature F. Additionally, antibody responses were significantly lower (1.4-1.5-fold) toward RSV/B than to RSV/A p27 at each study visit, despite being an RSV/B dominant outbreak. Understanding the mechanism for the differences in the magnitude of the RSV/A and RSV/B p27 antibody response may enhance our understanding of the intracellular processing of the F protein.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Furin cleavage site; Fusion protein; P27 peptide; Pneumovirus; Respiratory syncytial virus

Mesh:

Substances:

Year:  2021        PMID: 34903371      PMCID: PMC8755595          DOI: 10.1016/j.vaccine.2021.11.087

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  36 in total

1.  Cholesterol-rich microdomains as docking platforms for respiratory syncytial virus in normal human bronchial epithelial cells.

Authors:  Homero San-Juan-Vergara; Viviana Sampayo-Escobar; Niradiz Reyes; Byeong Cha; Lisandro Pacheco-Lugo; Terianne Wong; Mark E Peeples; Peter L Collins; Maria Eugenia Castaño; Shyam S Mohapatra
Journal:  J Virol       Date:  2011-11-16       Impact factor: 5.103

Review 2.  Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis.

Authors:  Harish Nair; D James Nokes; Bradford D Gessner; Mukesh Dherani; Shabir A Madhi; Rosalyn J Singleton; Katherine L O'Brien; Anna Roca; Peter F Wright; Nigel Bruce; Aruna Chandran; Evropi Theodoratou; Agustinus Sutanto; Endang R Sedyaningsih; Mwanajuma Ngama; Patrick K Munywoki; Cissy Kartasasmita; Eric A F Simões; Igor Rudan; Martin W Weber; Harry Campbell
Journal:  Lancet       Date:  2010-05-01       Impact factor: 79.321

3.  Small interfering RNA profiling reveals key role of clathrin-mediated endocytosis and early endosome formation for infection by respiratory syncytial virus.

Authors:  Andrey A Kolokoltsov; Drew Deniger; Elisa H Fleming; Norbert J Roberts; Jon M Karpilow; Robert A Davey
Journal:  J Virol       Date:  2007-05-09       Impact factor: 5.103

4.  Antigenic fingerprinting of RSV-A infected hematopoietic cell transplant recipients reveals importance of mucosal anti-RSV-G antibodies in control of RSV infection in humans.

Authors:  Sandra Fuentes; Megan Hahn; Katarina Chilcote; Roy F Chemaly; Dimpy P Shah; Xunyan Ye; Vasanthi Avadhanula; Pedro A Piedra; Hana Golding; Surender Khurana
Journal:  J Infect Dis       Date:  2019-11-20       Impact factor: 5.226

5.  Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis.

Authors:  P A Piedra; S Grace; A Jewell; S Spinelli; D Bunting; D A Hogerman; F Malinoski; P W Hiatt
Journal:  Pediatr Infect Dis J       Date:  1996-01       Impact factor: 2.129

6.  Risk of primary infection and reinfection with respiratory syncytial virus.

Authors:  W P Glezen; L H Taber; A L Frank; J A Kasel
Journal:  Am J Dis Child       Date:  1986-06

7.  A prospective surveillance study on the kinetics of the humoral immune response to the respiratory syncytial virus fusion protein in adults in Houston, Texas.

Authors:  Brittani N Blunck; Letisha Aideyan; Xunyan Ye; Vasanthi Avadhanula; Laura Ferlic-Stark; Lynn Zechiedrich; Brian E Gilbert; Pedro A Piedra
Journal:  Vaccine       Date:  2021-01-26       Impact factor: 3.641

8.  Sequence variability of the respiratory syncytial virus (RSV) fusion gene among contemporary and historical genotypes of RSV/A and RSV/B.

Authors:  Anne M Hause; David M Henke; Vasanthi Avadhanula; Chad A Shaw; Lorena I Tapia; Pedro A Piedra
Journal:  PLoS One       Date:  2017-04-17       Impact factor: 3.240

9.  Antibody Response to the Furin Cleavable Twenty-Seven Amino Acid Peptide (p27) of the Fusion Protein in Respiratory Syncytial Virus (RSV) Infected Adult Hematopoietic Cell Transplant (HCT) Recipients.

Authors:  Xunyan Ye; Wanderson Cabral de Rezende; Obinna Patrick Iwuchukwu; Vasanthi Avadhanula; Laura L Ferlic-Stark; Kirtida D Patel; Felipe-Andres Piedra; Dimpy P Shah; Roy F Chemaly; Pedro A Piedra
Journal:  Vaccines (Basel)       Date:  2020-04-21

Review 10.  Virus glycosylation: role in virulence and immune interactions.

Authors:  David J Vigerust; Virginia L Shepherd
Journal:  Trends Microbiol       Date:  2007-03-29       Impact factor: 17.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.